While amyloid and tau PET imaging offer higher specificity advantages for AD pathology, cerebral perfusion SPECT provides several practical advantages, including lower cost, wider accessibility (especially when cyclotron facilities are unavailable), and insurance coverage in multiple countries. The gene discussed is MAPT; the disease is Alzheimer disease.